The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence

Cancer

Volumn 103, Issue 5, 2005, Pages 884-891

  Janni, Wolfgang ^a   Rack, Brigitte ^a   Schindlbeck, Christian ^a   Strobl, Barbara ^a   Rjosk, Dorothea ^a   Braun, Stephan ^b   Sommer, Harald ^a   Pantel, Klaus ^c   Gerber, Bernd ^b   Friese, Klaus ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast neoplasm; Disseminated tumor cells; Isolated tumor cells; Neoplasm metastasis; Neoplasm recurrence; Survival

Indexed keywords

CYTOKERATIN ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A45 B B3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOASSAY; ISOLATED TUMOR CELL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REGRESSION ANALYSIS; TUMOR CELL; TUMOR VOLUME;

BONE MARROW; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; REGRESSION ANALYSIS; RISK; SURVIVAL RATE;

EID: 13944259758     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20834     Document Type: Article

References (39)

1. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-533.
2. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652-1658.
3. Gerber B, Krause A, Muller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol. 2001;19:960-971.
4. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21: 3469-3478.
5. Braun S, Vogl F, Schlimok G, et al. Pooled analysis of prognostic impact of bone marrow micrometastases: 10 year survival 4268 breast cancer patients [abstract 7]. Breast Cancer Res Treat. 2003;67(Suppl 1).
6. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
7. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev. 2002;CD000487.
8. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91:1113-1124.
9. Janni W, Hepp F, Rjosk D, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer. 2001;92:46-53.
10. Janni W, Strobl B, Schindlbeck C, et al. Persistence of occult metastatic cells in bone marrow of breast cancer patients despite systemic adjuvant treatment (abstract 21]. Breast Cancer Res Treat. 2001;65(1).
11. Wiedswang, G, Borgen, E, Karesen R, Qvist H, Naume B. The presence of isolated tumor cells in the bone marrow three years after diagnosis in disease free breast cancer patients predicts an unfavorable outcome [abstract 8]. Breast Cancer Res Treat. 2003;67(Suppl 1).
12. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000;18:80-86.
13. Singletary ES, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
14. Le DV, Tubiana HM, Friedman S, Hacene K, Spyratos F, Brunei M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64:1914-1921.
15. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother. 1994; 3:315-322.
16. Stigbrand T, Andres C, Bellanger L, et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol. 1998;19:132-152.
17. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
20. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991;9:1749-1756.
21. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol. 1992;10:1534-1539.
22. Courtemanche DJ, Worth AJ, Coupland RW, MacFarlane JK. Detection of micrometastases from primary breast cancer. Can J Surg. 1991;34:15-19.
23. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol. 1998; 16:557-566.
24. Salvadori B, Squicciarini P, Rovini D, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 1990; 26:865-867.
25. Untch M, Harbeck N, Eiermann W. [Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?]. Gynakol Rundsch. 1989;29(Suppl 2):231-233.
26. Untch M, Kahlert S, Funke I, et al. Detection of cytokeratin (CK) 18 positive cells in the bone marrow (BM) of breast cancer patients-no prediction of bad outcome [abstract]. Proc Am Soc Clin Oncol. 1999;18:693a.
27. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol. 2001;19:3669-3674.
28. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354: 197-202.
29. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327.
30. Camp RL, Dolled FM, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003;63:7-1448.
31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
32. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med. 2003;9:999-1000.
33. van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
34. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
35. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA. 2001;98:11462-11467.
36. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
37. Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002; 62:2162-2168.
38. Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res. 2004;10:5342-5348.
39. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802.